RO 8191

Product Description

RO 8191 is an IFNα receptor 2 (IFNAR2) agonist (EC₅₀ = 0.2 μM). RO 8191 induces phosphorylation and activation of STAT1 and STAT2. RO 8191 inhibits hepatitis C (HCV) cell culture-produced infectious particles and HCV subgenomic replicon (IC₅₀ values 0.20 μM and 0.17 μM, respectively) and inhibits hepatitis B virus replication in cell cultures (IC₅₀ = 0.1 μM). In an animal model RO 8191 inhibits prion invasion and prolongs survival; it also reverses the inhibitory effect of integrin β6 (ITGB6) on the JAK/STAT3 signaling and the epithelial-to-mesenchymal transition pathway and inhibits the proliferation, invasion, and migration of cervical cancer cells. Orally bioavailable.

Solubility

Preparing Stock Solutions for RO 8191

The following data is based on the product molecular weight 373.22

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.05 mM	53.59 mL	267.94 mL	535.88 mL
0.25 mM	10.72 mL	53.59 mL	107.18 mL
0.5 mM	5.36 mL	26.79 mL	53.59 mL
2.5 mM	1.07 mL	5.36 mL	10.72 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Ishibashi Type I interferon protects neurons from prions in in vivo models. Brain 2019 PMID: 30753318
• Zheng Silencing of ITGB6 inhibits the progression of cervical carcinoma via regulating JAK/STAT3 signaling pathway. Ann.Transl.Med. 2021 PMID: 34268416
• Furutani An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes. PLoS One 2019 PMID: 31188831
• Konishi An orally available, small-molecule interferon inhibits viral replication. Sci.Rep. 2012 PMID: 22355771